Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This study found that certain gene sets, including those involved in ligand-gated ion channel signaling and cell adhesion, are associated with Tourette syndrome, suggesting a potential neurobiological basis for the disorder.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

This article explores the therapeutic potential of TECAR therapy for physiotherapy, highlighting its non-invasive nature and ability to provide analgesic, anti-inflammatory, and tissue healing effects across various conditions with minimal side effects when applied correctly.

This study reports a case of a 59-year-old female with refractory follicular mucinosis and diffuse scalp alopecia who achieved complete clinical remission following treatment with a combination of topical tacalcitol and photodynamic therapy.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study reported six pediatric cases of temporal triangular alopecia and highlighted the use of trichoscopy to distinguish it by detecting a distinctive carpet of vellus hair, helping to differentiate TTA from other hair loss conditions.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This article reviews the use of dermoscopy in distinguishing temporal triangular alopecia from alopecia areata, emphasizing its role in avoiding invasive diagnostics and ineffective treatments; it reports no new clinical findings.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

This letter discusses congenital triangular alopecia (TTA), a non-scarring hair loss condition often seen in children, without reporting new clinical findings.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

ITK inhibitors may effectively treat alopecia areata.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

In this study, introducing the rat OTC gene into spf-ash mice led to increased OTC activity and normalized hair growth and biochemical markers like urinary orotic acid and serum citrulline, partially correcting the symptoms of OTC deficiency.

Triamcinolone acetonide injections help regrow hair in alopecia areata patients.